Registered human trialRecruitingNo efficacy data yet

Phase 1/2

ReVIVE

Clemastine • chronic demyelination

Compound / intervention: Clemastine • chronic demyelination
Mechanism: Clemastine; muscarinic-receptor antagonism
Development stage: Phase 1/2
Status: Recruiting
Population / locations: Site: UCSF, US • no Greek site
Evidence level: Human Phase 1/2 • results pending

Next substantive checkpoint

Multiparametric MRI for changes in myelin • estimated completion 2027

ClinicalTrials.govOpen source ↗Last checked: 16 Sep 2026

Related substantive developments

No separate substantive update is currently linked.